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INTRODUCTION
Epidermal growth factor receptor (EGFR)-tyrosine kinase in-
hibitors (EGFR-TKIs) have profoundly improved available 
management strategies for EGFR-mutated non-small cell lung 
cancer (NSCLC) by achieving a superior response rate, pro-
gression-free survival (PFS) rate, and quality of life than vari-
ous available cytotoxic agents.1 Therefore, they have become 
the established standard treatment for patients with EGFR-
mutant NSCLC;2,3 nevertheless, these patients typically exhibit 
acquired resistance to EGFR-TKIs (including gefitinib, erlotinib, 
and afatinib) after a median period of 1 year. Of these, approxi-
mately 60% develop a T790M gatekeeper mutation in the EGFR 
exon 20 kinase domain.4-6
Osimertinib was the first oral, irreversible EGFR-TKI to re-
ceive approval from the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) to be used 
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as a treatment for advanced EGFR-mutant NSCLC cases ex-
hibiting acquired EGFR T790M resistance mutations.7 A pre-
vious (AURA3) study demonstrated that, compared to treat-
ment with chemotherapy, osimertinib treatment significantly 
improved PFS time (median PFS, 4.4 vs. 10.1 months; p<0.001) 
and objective response rate (ORR) (31% vs. 71%, p<0.001) of 
patients with T790M-positive advanced NSCLC (after previ-
ous first-line EGFR-TKI treatment).8
Therefore, the introduction of osimertinib has rendered the 
ability of clinicians to detect T790M mutations essential in the 
clinical setting, to ensure that patients receive the most appro-
priate treatment available.9 However, it is technically difficult 
to perform and collect an adequate sample volume from lung 
tissue biopsies; therefore, rebiopsy can be a clinical barrier to 
assessing a patient’s EGFR mutation status. Moreover, obtain-
ing a new tissue sample at the time of progression is often in-
vasive, expensive, more technically difficult than an initial tis-
sue biopsy, and sometimes infeasible.10 
Recently, noninvasive plasma EGFR genotyping emerged 
as a novel method to detect EGFR mutations, including T790M. 
In fact, the US FDA has now approved the use of osimertinib 
in NSCLC cases confirmed to harbor an EGFR T790M muta-
tion via noninvasive plasma EGFR genotyping, whether or not 
tumor tissue is available for screening using standard meth-
ods.11 Some genotyping platforms for analyzing circulating tu-
mor DNA (ctDNA) have already received regulatory approval 
and been introduced into the clinical setting (for use in com-
bination with retrospective and prospective validation meth-
ods), and many more are likely to do so in the near future. 
Current methods to detect EGFR mutations via various plat-
forms include direct and next-generation sequencing, the 
“scorpion” amplified refractory mutation system, and poly-
merase chain reaction (PCR) techniques including peptide 
nucleic acid clamping, droplet digital PCR, and beads, emul-
sions, amplification and magnetics (BEAMing) PCR. Each of 
these various platforms has a range of advantages and disad-
vantages, and detects EGFR mutations with varying sensitivity 
and specificity in patients who are treatment-naïve, compared 
to those who exhibit acquired resistance.12 In particular, liquid 
biopsies to detect T790M mutations are essential in cases of 
progressed EGFR-mutated NSCLC (after treatment with first 
or second-generation EGFR-TKIs), for which tumor tissue is 
unavailable or scanty.13 
The recently conducted ASTRIS (NCT02474355) trial was an 
open-label, single-arm, multinational, real-world treatment 
study that investigated the safety and efficacy of using osimer-
tinib to treat patients with T790M-positive advanced NSCLC, 
who had previously been administered a first- and/or second-
generation EGFR-TKI.14 In the present study, we aimed to in-
vestigate the success rate of tissue rebiopsies that were con-
ducted, and the incidence of T790M mutations in tissue and 
plasma samples that were collected upon NSCLC progression 
from patients enrolled in the ASTRIS study. Furthermore, we 
evaluated whether the efficacy of osimertinib treatment was 
associated with the detection of T790M mutations in patient 
tissue and/or plasma samples.
MATERIALS AND METHODS
Patient enrollment and data collection
All patients with NSCLC, who were screened for the ASTRIS 
study over a 1-year period at Yonsei Cancer Center (Seoul, Ko-
rea), were included and analyzed in the present study. The in-
clusion criteria for the ASTRIS study required that patients be 
aged ≥20 years, exhibit histologically or cytologically 
confirmed NSCLC with EGFR mutation that progressed after 
initial EGFR-TKI treatment, and have a confirmed EGFR 
T790M mutation in their tissue and/or plasma sample(s) dur-
ing or after this progression. Tumor rebiopsy was recom-
mended in all cases, and performed upon approval by treat-
ing physician. The objectives of this study were to assess the 
efficacy of rebiopsy and EGFR mutation test of tissue and plas-
ma samples in drug resistant NSCLC in the real world. Data 
were collected to describe patient characteristics, baseline 
EGFR mutation status, utilized rebiopsy techniques and sites, 
identified patient tissue (and/or cytology) and plasma EGFR 
mutation statuses, reasons for foregoing a rebiopsy (in appro-
priate patients), and clinical efficacy parameter of osimertinib 
among osimertinib-treated patients. 
EGFR mutational analysis
A peptide nucleic acid (PNA) ClampTM EGFR Mutation Detec-
tion Kit (PANAGENE Inc., Daejeon, Korea) was used to detect 
EGFR mutations in sample tissues via a real-time PCR, as pre-
viously described.15 Likewise, EGFR mutations were detected 
in plasma samples via the PANAMutyper method, using a 
PANAMutyperTM EGFR kit (PANAGENE Inc.), as previously 
described.16 Briefly, these techniques used specific PNA de-
tection clamp probes to tightly bind, and thereby suppress the 
amplification of wild-type (WT) DNA sequences, and fluores-
cent dye- and quencher-conjugated PNA detection probes to 
specifically detect target mutant DNA sequences. Mutations 
were genotyped via a melting peak analysis.
Assessment of ASTRIS study findings
The present study evaluated real-world rebiopsy data collect-
ed from the ASTRIS patient cohort, including the frequency, 
selected site and method, success rate, and complication rate 
of the conducted rebiopsies. It also assessed the detected inci-
dence of T790M mutations, and analyzed the level of agree-
ment between EGFR test results that were generated using 
plasma and tissue samples. Clinical efficacy of osimertinib 
treatment among the ASTRIS cohort of patients was evaluated 
by assessing patient outcomes, including the ORR, disease con-
trol rate (DCR), PFS time/rate, and overall survival (OS) time/
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rate, as recommended by the Response Evaluation Criteria in 
Solid Tumors (RECIST), version 1.1. Patient PFS time was de-
fined as the period starting from the first day of osimertinib 
administration to the date of progression or death from any 
cause. OS time was defined as the interval extending from the 
first day of osimertinib administration to the date of last follow-
up or of death from any cause.
Statistical analysis
Patient survival distribution was estimated using the Kaplan-
Meier method, where p value <0.05 was considered statistically 
significant. The agreement between tumor tissue (and/or cy-
tology) and plasma EGFR mutation tests was assessed using 
positive percent agreement (PPA), negative percent agree-
ment (NPA), and the overall percent agreement (OPA). All sta-
tistical analyses were performed using SPSS software, version 
23.0 (IBM Corp., Armonk, NY, USA). 
Ethical approval
Informed consent was obtained from all individual partici-
pants included in the study, which was approved by the Yonsei 
Cancer Center Institutional Review Board, Severance Hospital 
(IRB no. 4-2016-0001). 
RESULTS
Patient population
A total of 188 patients with NSCLC were screened for the AS-
TRIS study at Yonsei Cancer Center between April 2016 to De-
cember 2016 (Table 1). Clinical data was based on a data cut-
off from June 1, 2017. The median age of patients at study 
entry was 61 years (range 31–88 years), and all patients were 
histologically confirmed to exhibit adenocarcinoma. At the 
time of initial diagnosis, 53.7% (n=101) and 41.5% (n=78) of 
patients were found to harbor activating EGFR exon 19 dele-
tion and exon 21 L858R mutations, respectively, while 4.8% 
(n=9) patients instead exhibited rare EGFR mutations. Most 
ASTRIS patients responded to the initial administration of 
EGFR-TKIs [ORR, 71.8%; 95% confidence interval (CI), 65.0–
Table 1. Demographic and Clinical Characteristics of the Study Patients
Rebiopsy group (n=112) Non-rebiopsy group (n=76) Total (n=188)
Age (yr), median (range) 61 (31–85) 61 (39–88) 61 (31–88)
Sex
Male 38 (34.0) 22 (28.9) 60 (32)
Female 74 (99.0) 54 (71.1) 128 (68)
Smoking status*
Current smoker 10 (8.9) 6 (7.9) 16 (8.5)
Former smoker 17 (15.2) 9 (11.8) 26 (13.8)
Never smoker 81 (72.3) 58 (76.3) 139 (73.9)
Unknown 4 (3.6) 3 (3.9) 7 (3.7)
Performance status (ECOG)
0–1 103 (92.0) 71 (93.4) 174 (92.6)
2–4 9 (8.0) 5 (6.6) 14 (7.4)
Baseline EGFR mutation
Exon 19 deletion 65 (58.0) 36 (47.4) 101 (53.7)
Exon 21 L858R 43 (38.4) 35 (46.1) 78 (41.5)
Others 4 (3.6)† 5 (6.6)‡ 9 (4.8)
Response to initial EGFR TKI
CR 1 (0.9) 0 (0.0) 1 (0.5)
PR 84 (75.0) 50 (65.8) 134 (71.3)
SD 13 (11.6) 12 (15.8) 25 (13.3)
Not evaluable 14 (12.5) 14 (18.4) 28 (14.9)
Line of therapy
1 50 (44.6) 46 (60.5) 96 (51.1) 
2 22 (19.6) 13 (17.1) 35 (18.6)
3 or more 40 (35.7) 17 (22.4) 57 (30.3)
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; TKI, tyrosine-kinase inhibitor; CR, complete response; PR, partial response; 
SD, stable disease.
Variables are presented as a number (percentage) unless otherwise noticed.
*Current smoker, who currently smokes or has quit smoking for less than 1 year; former smoker, who has stopped smoking for more than 1 year; never smoker, a 
lifetime smoking dose of fewer than 100 cigarettes, †All four patients had EGFR G719X mutation, ‡EGFR mutation status were as follows: EGFR 19del+T790M (n= 
1), G719X (n=2), S768I (n=1), and S768I+G719X (n=1).
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77.8%]. Only 51.1% of patients were exposed to one line of EG-
FR-TKI. A total of 23.4% (n=44) of patients were treated with 
two or more EGFR-TKIs, including seven patients who were 
administered another third-generation EGFR-TKI, olmutinib. 
Rebiopsy feasibility after EGFR-TKI resistance 
acquisition
Among the ASTRIS cohort of 188 patients, 112 (59.5%) under-
went rebiopsy. Rebiopsy was performed after the progression 
upon first- or second-generation EGFR-TKIs. Conversely, 76 
(40.4%) patients did not undergo rebiopsy for various reasons; 
for example, in 37 cases, the treating physician decided against 
rebiopsy (Fig. 1). Among them, 20 patients did not undergo a 
rebiopsy (as per the ASTRIS study guidelines), as their plasma 
samples had already been detected to harbor T790M muta-
tions. In addition, 17 patients whose plasma samples were 
initially confirmed to be T790M-negative were managed by a 
“treatment-beyond-progression” strategy using previously 
administered EGFR-TKIs based on the treating physician’s 
decision, and therefore, did not undergo a tissue rebiopsy. 
Moreover, 28 patients exhibited tumors that were inaccessible 
for rebiopsy, most (n=23) of which comprised small lung met-
astatic nodules, and four and one patient displayed only intra-
cranial and skeletal cancer progression, respectively. Finally, five 
patients refused to undergo rebiopsy, and a further five were not 
able to undergo the rebiopsy procedure due to their poor per-
formance status. 
Of the 112 patients who did undergo rebiopsy, 18 had to 
undergo multiple biopsies to collect sufficient tumor tissue to 
enable EGFR mutation testing. In fact, two patients required a 
third biopsy, and furthermore, four patients failed to receive a 
valid mutation test result even after multiple biopsies. Overall, 
the rate of successful pathological confirmation of the rebiop-
sied tissues was 84.8% (95/112); however, in three of 95 cases, 
inadequate tissue was collected from the rebiopsy to com-
plete EGFR mutation test. Therefore, excluding these and two 
other patients who underwent successful rebiopsy, but did 
not undergo EGFR mutation testing after T790M mutations, 
were detected in their plasma samples, and the overall suc-
cess rate of tissue rebiopsy and subsequent EGFR mutation 
analysis among the ASTRIS cohort was 81.8% (90/110). 
 Among 88 patients who had undergone rebiopsy and could 
provide the information on initial biopsy, initial biopsy site 
were lung (n=82), pleural effusion (n=4), and neck lymph node 
(n=2). Among 82 patients whose initial biopsy site were lung, 
67.1% of patients received rebiopsy in lung (n=55). For patients 
who had been diagnosed with pleural effusion sample only, 
rebiopsy with thoracentesis was done in one case and other 
rebiopsy targets included lung (n=2) and neck lymph node 
(n=1). For two patients who had undergone neck lymph node 
biopsy for initial diagnosis, one patient got neck lymph node 
biopsy and the other one underwent thoracentesis.
Rebiopsy methods, and success and complication rates
Various methods were used for rebiopsy patients (Table 2). Of 
the 112 patients who underwent rebiopsy, 49 (43.8%) were 
subjected to bronchoscopy, including endobronchial biopsy, 
fluoroscopy-guided transbronchial lung biopsy (TBLB), or 
endobronchial ultrasound (EBUS)-transbronchial needle as-
piration (TBNA). Of these methods, bronchoscopy with fluo-
roscopy-guided TBLB was most commonly used (n=24). The 
tumor acquisition rate achieved via this method and endo-
bronchial biopsy method was 75.0% and 83.3%, respectively, 
and all methods were successfully employed to produce valid 
Rebiopsy not tried (n=76; 40.4%)
physician’s decision: 37 (omitting on purpose based 
on plasma T790M positive: 20,  
continue current treatment: 17)
inaccessible tumor sites: 28
patient’s refusal: 5
poor performance status: 5
unknown: 1
-  Insuifficient tissue for EGFR mutation test: 3
-  Decided to omit tissue EGFR mutation 
test on purpose due to positive plasma 
T790M: 2
-  Plasma T790M status 
Positive: 4 
Negative: 1
188 patients screened
-  Plasma T790M status 
Positive: 5 
Negative: 12
Pathologic diagnosis 
(n=95; 84.8%)
Pathologic diagnosis failed 
(n=17; 15.2%)
Tissue EGFR mutation analysis 
(n=90; 94.7%)
-  Tissue T790M negative (n=42; 46.7%)
-  Plasma T790M status 
Positive: 13 
Negative: 29
-  Tissue T790M positive (n=48; 53.3%)
-  Plasma T790M status 
Positive: 11 
Negative: 22 
Unknown: 15
Rebiopsy undergone (n=112; 59.5%) -  Plasma T790M status 
Positive: 24 
Negative: 52
Fig. 1. CONSORT diagram. EGFR, epidermal growth factor receptor.
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EGFR mutation-test results. However, in one patient, all three 
bronchoscopic procedures were employed, and yet an appro-
priate tumor tissue sample could not be collected.
Twenty-three patients underwent percutaneous lung biop-
sy. The majority (78.3%, 18/23) of these patients were subject-
ed to CT-guided percutaneous needle biopsy, with a success 
rate of 77.8% (14/18). Tumor acquisition rate of 100% was ob-
served in neck lymph node biopsy (n=10), video-assisted tho-
racoscopic surgery (n=6), and brain surgery (n=2). In addition, 
a high pathological confirmation rate was achieved using vari-
ous effusion sample types (i.e., pleural effusion, 81.8%, 9/11; 
ascites, 100%, 3/3).
Only one case each of significant bleeding (2.0%, 1/49) and 
pneumothorax (5.5%, 1/18) was observed among the rebiop-
sied patients, after bronchoscopy and CT-guided percutaneous 
lung biopsy, respectively. No clinically significant complica-
tions resulted from procedures that targeted non-lung tissues.
EGFR mutation test results
Of the 90 patients who underwent rebiopsy and received valid 
EGFR mutation test results, 53.3% (48/90) were found to harbor 
T790M mutation. Notably, the detection rate of tissue T790M 
mutation in all patients who progressed first or second-gener-
ation EGFR-TKIs was only 25.5% (48/188). Endobronchial bi-
opsy, fluoroscopy-guided TBLB, and CT-guided percutaneous 
lung biopsy methods were used to identify EGFR T790M muta-
tions in 50.0, 38.9, and 64.3% of applied cases, respectively. 
Similarly, EGFR T790M mutations were identified in all six pa-
tients who underwent rebiopsy via VATS, and all three pa-
tients whose malignant ascites was sampled via paracentesis. 
In contrast, T790M mutation was only detected in 16.7% and 
25.0% of liver tissue and cerebrospinal fluid samples, respec-
tively, and was not identified in any rebiopsied brain-tumor nor 
bone tissue samples. 
Agreement between EGFR genotyping results generated 
using tissue and plasma samples
Plasma samples were collected in all 76 patients who were not 
rebiopsied, and genetic testing detected T790M mutations in 
24 (31.6%) cases. Of the 188 patients in the ASTRIS cohort, 75 
provided matched tumor tissue and plasma samples, whereas 
98 and 15 patients only provided plasma or tissue samples, re-
spectively, for EGFR genotyping. A comparison of these matched 
samples revealed the positive predictive value of plasma T790M 
mutation screening to be 45.8% (11/24), and the false-positive 
rate among screened plasma samples to be 54.2% (13/24) 
(Table 3).
The overall PPA (sensitivity), NPA (specificity), and OPA of the 
plasma with tissue T790M-screening results was 33.3% (95% CI, 
19.7–50.5%), 69.1% (95% CI, 53.9–81.0%), and 53.3% (95% CI, 
42.2–64.2%), respectively. Notably, the utilized PNA-clamping 
genotyping method detected the activating EGFR mutations 
(i.e., the EGFR 19 deletion and L858R mutation) more effective-
ly. For example, OPA and NPA between plasma and tissue 
screening for L858R mutation was 88.0% (95% CI, 78.5–93.8%) 
and 94.1% (95% CI, 83.5–98.6%), respectively (Table 4).
Table 2. Rebiopsy Methods and Their Success Rate and Complications (n=112)
Site Method
Number 
of patients
Success,  
n (%)
T790M reported,  
No. of patients with successful 
tissue biopsy, n (%)
Complications
Intrathoracic site
Lung parenchyme Bronchoscopic endobronchial biopsy only 12 10 (83.3)  5 (50.0) None
Bronchoscopic biopsy with TBLB 24 18 (75.0)  7 (38.9)
Bleeding 
(clinically significant), 1
CT-guided percutaneous lung biopsy 18 14 (77.8)  9 (64.3) Pneumothorax, 1
US-guided lung biopsy 5 4 (80.0) 3 (75.0) None
Biopsy under VATS 6 6 (100) 6 (100) None
Mediastinal lymph node EBUS-TBNA 14 11 (78.6)  6 (54.5) None
Pleural effusion Thoracentesis 11 9 (81.8)  4 (44.4) None
Extrathoracic site
Neck node US-guided lymph node biopsy 10 10 (100)  6 (60.0) None
Liver US-guided liver biopsy 7 6 (85.7)  1 (16.7) None
CSF Spinal tapping 7 4 (57.1)  1 (25.0) None
Ascites Paracentesis 3 3 (100) 3 (100) None
Bone Bone biopsy via CT 2 2 (100) 0 (0.0) None
Skin Skin biopsy 2 1 (50.0)  1 (100) None
Brain Brain surgery 2 2 (100) 0 (0.0) None
TBLB, transbronchial lung biopsy; US, ultrasound; VATS, video-assisted thoracoscopic surgery; EBUS, endobronchial ultrasound; TBNA, transbronchial needle as-
piration; CSF, cerebrospinal fluid.
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Association of osimertinib efficacy with tissue and/or 
plasma EGFR T790M mutation statuses
ORR among the 88 patients who were eligible for, and were ad-
ministered treatment with osimertinib as part of the ASTRIS 
trial, was 44.3% (95% CI, 34.4–57.2%) (Table 5). Notably, ORR 
was highest (57.8%) in patients who exhibited T790M-positive 
tumor tissue samples, modest (35.2%) in those who exhibited 
T790M-positive plasma samples, and lowest (7.6%) in those 
who exhibited a plasma samples that was positive, but a tissue 
samples that was negative for T790M mutation. Importantly, 
ORR of patients who exhibited T790M-positive tumor-tissue 
samples was greater than 50%, (57.8% in those with T790M-
positive tissue, 54.5% in T790M-positive tissue/plasma, and 
52.6% in T790M-positive tissue/ T790M-negative plasma sam-
ples), regardless of their plasma test results. Likewise, the over-
all DCR was 78.4% (95% CI, 68.6–85.8%) among the 88 patients 
treated with osimertinib, but 100% among patients who pro-
vided T790M-positive tissue/T790M-negative plasma samples. 
During osimertinib treatment follow-up (median follow-up 
period, 25.1 weeks), the 88 patients exhibited a median PFS 
time of 32.7 weeks (95% CI, 26.6–38.3 weeks), and did not reach 
a median OS time. Notably, the median PFS time was signifi-
cantly longer (45.0 weeks) in 45 patients that exhibited T790M-
positive tumor tissue samples (95% CI, 38.0–52.0 weeks) than in 
13 patients who exhibited T790M-negative tissue and T790M-
positive plasma samples (9.4 weeks; 95% CI, 7.2–11.0 weeks; 
p<0.0001) (Fig. 2A). Similarly, dividing the patients into tissue 
T790M-positive and plasma T790M-positive groups revealed a 
marked difference in their median PFS time, which was 45.0 
and 20.4 weeks (hazard ratio=0.38; p=0.0005), respectively (Fig. 
2B). In tissue T790M-positive patients (n=45), the median PFS 
was not reached, 48.1 weeks, and 20.4 weeks in T790M plasma-
negative, unknown, and positive patients, respectively 
(p=0.0029) (Fig. 2C). Furthermore, plasma T790M-positive pa-
tients (n=54) who exhibited tissue samples that were T790M-
unknown, -positive, and -negative displayed a median PFS time 
of 31.9, 20.4, and 9.4 weeks, respectively (p=0.0065) (Fig. 2D).
DISCUSSION
Since the third-generation EGFR-TKI osimertinib was demon-
strated to be significantly more effective than various cytotoxic 
agents used to treat T790M-mutant NSCLC, rebiopsy upon 
NSCLC progression has become an established part of stan-
dard care for these patients.8 Clinical use of osimertinib requires 
confirmation of the presence of T790M mutation in tumor tis-
sues; however, a substantial portion of patients do not currently 
undergo tissue rebiopsy due to a range of reasons, including 
poor performance status after progression, comorbidity, un-
availability of next-line of therapies, inaccessible tumor locations, 
patient refusal, etc.17-19 In addition, the current yield of rebiopsy 
samples is only sufficient for genetic screening in approximately 
70–80% of cases.10,20-22 Therefore, non-invasive collection and 
screening of cell-free plasma or urine DNA has been suggested 
as an alternative method to overcome these limitations. Various 
assays with varying sensitivities and specificities have been, 
and continue to be, developed to screen these sample types.23 
However, to date, only the cobas EGFR Mutation Test kit (v.2, 
Roche Molecular Systems, Inc., Pleasanton, CA, USA) has been 
approved by the FDA for plasma genotyping in the clinical set-
ting.24 Given the current limitations of tissue rebiopsy methods, 
continued development and optimization of such assays are 
essential to improve outcomes for patients with EGFR-mutant 
NSCLC.
In the present study, we investigated the frequency, meth-
od, and success rate of tissue rebiopsy, and evaluated the inci-
dence of T790M mutations identified in tissue and plasma sam-
ples collected from a cohort of real-world patients upon their 
acquisition of resistance to first or second-generation EGFR-
TKIs. To the best of our knowledge, this is the largest dataset to 
date to prospectively analyze and compare the real-world effica-
cy of tissue rebiopsy and plasma genotyping. 
In the current study, overall rebiopsy rate was approximately 
60%, consistent with previous studies.10,21 Among 188 patients 
who progressed upon EGFR-TKIs, only a quarter of patients 
were proven to have tissue T790M EGFR mutations (n=48), but 
the positive rate of T790M was 53.3% in available EGFR muta-
tion result (n=48/90), which was consistent with historical data.8 
The most common site of tissue rebiopsy was the lung, and the 
Table 3. Comparison of T790M Status between Plasma and Tissue Samples (n=188)
Plasma T790M+ (n=57) Plasma T790M- (n=116) Plasma test not performed (n=15)
Tissue T790M+ (n=48) 11 22 15
Tissue T790M- (n=42) 13 29 0
Tissue EGFR test not performed (n=98) 33 65 0
EGFR, epidermal growth factor receptor.
Table 4. Percent Agreement of Plasma Assays (PANAMutyperTM) with 
Tissue Genotype (PNAClampTM) as Reference Standard for EGFR Exon 19 
Deletion, L858R Mutation, and T790M Mutation at the Time of Progression 
Upon EGFR-TKIs (n=75)
Percent agreement (95% CI), %
Exon 19 deletion L858R mutation T790M mutation
PPA 46.1 (31.6–61.4) 53.1 (36.5–69.1) 33.3 (19.7–50.5)
NPA 94.4 (80.9–99.4) 94.1 (83.5–98.6) 69.1 (53.9–81.0)
OPA 69.3 (58.1–78.7) 88.0 (78.5–93.8) 53.3 (42.2–64.2)
EGFR, epidermal growth factor receptor; TKI, tyrosine-kinase inhibitor; CI, con-
fidence interval; PPA, positive percent agreement; NPA, negative percent 
agreement; OPA, overall percent agreement.
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most commonly utilized rebiopsy technique was a lung biopsy 
via bronchoscopy (n=49, 42.2%), followed by a percutaneous 
lung biopsy, as previously described.20,22,25 Notably, pleural ef-
fusion and ascites samples, which are considered to be easily 
accessible sample types, were shown to be a good source of DNA 
for EGFR mutation testing. The two sample types provided a 
Table 5. Response Summary of Osimertinib according to the Source of T790M Status
Total
(n=88)
Tissue  
T790M+
(n=45)
Plasma  
T790M+
(n=54)
Tissue T790M+  
& Plasma T790M+ 
(n=11)
Tissue T790M+  
& Plasma T790M- 
(n=19)
Tissue T790M-   
 & Plasma T790M+ 
(n=13)
Best response
CR or PR 39 (44.3) 26 (57.8) 19 (35.2) 6 (54.5) 10 (52.6) 1 (7.6)
SD 30 (34.1) 15 (33.3) 16 (29.6) 1 (9.1) 9 (47.4) 3 (23.1)
PD 13 (14.8) 3 (6.7) 13 (24.1) 3 (27.3) 0 (0.0) 7 (53.8)
Not evaluable 6 (6.8) 1 (2.2) 6 (11.1) 1 (9.1) 0 (0.0) 2 (15.4)
ORR (95% CI), (%) 44.3 (34.4–57.2) 57.8 (43.3–71.0) 35.2 (23.8–48.6) 54.5 (28.0–78.8) 52.6 (31.7–72.7) 7.6 (0.0–35.4)
DCR (95% CI), (%) 78.4 (68.6–85.8) 91.1 (78.7–97.0) 64.8 (51.5–76.2) 63.6 (35.2–85.0) 100.0 (80.2–100.0) 30.8 (12.4–58.0)
CR, complete response; PR, partial response; SD, stable disease; ORR, objective response rate; DCR, disease control rate; CI, confidence interval
Variables are presented as a number (percentage) unless otherwise noticed.
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532
Real-World Data on the Rebiopsy in EGFR-Mutant NSCLC
https://doi.org/10.3349/ymj.2019.60.6.525
sufficient sample volume for EGFR screening in 81.8% and 
100% of cases, respectively, and 100% of the collected malig-
nant ascites fluid samples were found to harbor T790M muta-
tion. Likewise, T790M mutations were detected in all surgical 
lung rebiopsy samples (n=6), suggesting that this is a promis-
ing DNA source for patients able to tolerate general anesthesia 
and surgery. In only one case, we identified T790M mutation 
in cerebrospinal fluid. Rebiopsy complication rate in the pres-
ent study was negligible, comprising only a single case each of 
bleeding and pneumothorax resulting from bronchoscopic bi-
opsy and CT-guided lung biopsy, respectively. Together, these 
findings highlight the clinical importance and advantages of 
identifying feasible (including non-standard) rebiopsy sites to 
facilitate the collection of tissue and/or body fluid samples for 
T790M mutation screening. 
Liquid biopsies, including EGFR genotyping assay used to 
screen ctDNA in patients with NSCLC in the present study, are 
being rapidly established as effective diagnostic tools in clini-
cal practice. A combined analysis of the previously conducted 
AURA extension (NCT01802632) and AURA2 (NCT02094261) 
studies showed that the cobas EGFR Mutation Test detected 
the plasma T790M mutation with PPA, NPA, and OPA levels of 
61% (95% CI, 57–66%), 79% (95% CI, 70–85%), and 65% (95% 
CI, 61–69%) against the tissue result as reference.26 Further-
more, a previous report showed a PNA clamp-assisted melt-
ing curve method similar to the one used in the present study 
to exhibit a 56.3% overall concordance rate in the detection of 
T790M mutation between plasma and tissue result at the time 
of disease progression.27 While this previous study only ana-
lyzed a small patient cohort (n=16), our present study demon-
strated a similar finding (OPA, 53.3%; 95% CI, 42.2–64.2%) us-
ing a much larger patient population (n=75). Notably, both the 
current and the previous study reported markedly lower NPA, 
OPA, and particularly PPA levels compared to those calculated 
for combined AURA extension/AURA2 data. This discrepancy 
may be a result of differences in the respective sample sizes and 
threshold values used by the three studies; therefore, further 
validation of the present findings using a larger set of paired 
samples is needed to confirm their clinical implications.
The secondary objective of the present study was to exam-
ine whether the clinical outcomes of osimertinib treatment in 
the patient cohort was correlated with the patient T790M sta-
tus and/or the utilized DNA source (i.e., tissue or plasma). Ox-
nard, et al.28 previously published an excellent and timely study, 
in which they screened ctDNA collected from patients with 
advanced NSCLC who received osimertinib treatment. That 
study reported a very similar median PFS time for tissue T790M-
positive and plasma T790M-positive patients (9.7 months; 95% 
CI, 8.3–12.5 months, and 9.7 months; 95% CI, 8.3–11.1 months, 
respectively), and therefore suggested that EGFR mutation 
analysis of liquid rebiopsied ctDNA may be a promising alter-
native method to detect T790M mutations. In contrast, the 
present study showed tissue and plasma T790M-positive pa-
tients to have remarkably different ORR and median PFS times 
(plasma, 35.2% and 20.4 weeks respectively; tissue, 57.8% and 
45.0 weeks, respectively). Therefore, the efficacy of osimer-
tinib in the present study was less predictable from the results 
of the plasma compared to tissue screening. This discrepancy 
may be a result of the fact that, unlike in the study by Oxnard, 
et al.,28 a high proportion of patients in the present study who 
exhibited T790M-positive plasma samples (n=54) provided 
tissue samples that were T790M-negative (n=13, 24.1%) or 
-unknown (n=30, 55.6%). In fact, only 20.3% (11/54) of plasma 
T790M-positive cases provided T790M-positive tissue sam-
ples. The median PFS time reported by the previous and the 
present study for tissue T790M-negative/plasma T790M-posi-
tive patients was very similar (2.8 months and 9.4 weeks, re-
spectively). Therefore, the seemingly inferior efficacy of osimer-
tinib in plasma T790M-positive patients in the present study is 
likely reflective of the high false-positive rate (54.2%, 13/24) 
incurred by the utilized plasma PNA clamping-assisted fluo-
rescence melting curve analysis method (Table 3). Another 
previous study used the BEAMing technique to screen plasma 
samples for T790M mutation with a success rate of 13.9%.26 
The results of the present study identified a number of dif-
ferences between the plasma and tissue T790M-positive pa-
tients. For example, plasma T790M-positive patients exhibited 
poorer baseline characteristics, and received more extensive 
treatment than tissue T790M-positive patients. For example, 
patients from these two groups predominantly received three 
and one line of therapy, respectively. Furthermore, 50% (27/54) 
of the plasma and only 24.4% (11/45) of tissue T790M-positive 
patients were previously treated with three or more therapy 
regimens. In addition, a greater proportion of plasma (74.1%, 
40/54) than tissue (48.9%, 22/45) T790M-positive patients de-
veloped baseline central nervous system metastases. While the 
present study reported a shorter median PFS for plasma T790M-
positive patients than was demonstrated by Oxnard, et al.,28 
both studies showed tissue T790M-negative patients to exhibit a 
markedly shorter median PFS time than T790M-positive or -un-
known patients (Fig. 2D).
Also consistent with the study by Oxnard, et al.,28 19 of the 
present plasma T790M-negative cases that exhibited discor-
dant tissue T790M-positivity experienced excellent patient out-
comes, including 52.6% ORR, 100.0% DCR, and failure to reach 
a median PFS within the duration of follow-up period (Fig. 2C). 
In fact, this PFS time was better than that experienced by plas-
ma/tissue T790M-positive cases (median PFS time, 20.4 weeks). 
It may be that, in the absence of circulating T790M clones, the 
presence of T790M-positive tumors may indicate a more in-
dolent form of NSCLC, which is characterized by a better 
prognosis and better predicted response to the administration 
of third-generation EGFR-TKIs.
The current study had several limitations, including the fact 
that all data were collected at a single center. This may have im-
pacted the study by biasing the selection of rebiopsy sites and 
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methods, since either or both are largely dependent on cost, 
facility protocols and capabilities, as well as the preferences, 
experience, and skill of treating physicians. In addition, since 
our center is a tertiary cancer center, most of the analyzed pa-
tients received extensive treatment for NSCLC, as evidenced by 
the fact that more than 30% were administered three or more 
lines of therapy prior to their participation in the ASTRIS trial. 
Also, the total number of the study participants was 188, but 
the number of tissue T790M or plasma T790M cases were just 
33 and 23, respectively. Considering these small numbers, in-
terpretation of our results should be accompanied with caution. 
Finally, only 51.1% of the analyzed patients exhibited NSCLC 
progression after treatment with a single line of EGFR-TKI 
therapy, and only a very limited number (n=7) of patients who 
were exposed to an alternative third-generation EGFR-TKI (ol-
mutinib) were included in the study. 
In conclusion, in the current real-world clinical settings, 
NSCLC rebiopsy upon resistance acquisition to EGFR-TKIs is 
increasingly important to facilitate the administration of third-
generation EGFR-TKIs. The findings of the present study high-
light the potential advantages of screening non-standard patient 
sample types, including ascites, and pleural effusion samples, 
for T790M mutations. The study also shows that, while their col-
lection is less invasive, plasma samples may be insufficient to 
generate accurate or reliable T790M test results with currently 
available genotyping platforms. Therefore, continued research 
is needed to develop and evaluate the efficacy of novel geno-
typing platforms for EGFR genotyping using plasma samples.
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